These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25060052)

  • 21. Serum fibroblast growth factor-23 and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study.
    Fyfe-Johnson AL; Alonso A; Selvin E; Bower JK; Pankow JS; Agarwal SK; Lutsey PL
    J Hypertens; 2016 Jul; 34(7):1266-72. PubMed ID: 27100793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum 25-hydroxyvitamin D level and kidney function decline in a Swiss general adult population.
    Guessous I; McClellan W; Kleinbaum D; Vaccarino V; Hugues H; Boulat O; Marques-Vidal P; Paccaud F; Theler JM; Gaspoz JM; Burnier M; Waeber G; Vollenweider P; Bochud M
    Clin J Am Soc Nephrol; 2015 Jul; 10(7):1162-9. PubMed ID: 25901090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kidney function, bone-mineral metabolism markers, and future risk of peripheral artery disease.
    Yang C; Kwak L; Ballew SH; Garimella PS; Jaar BG; Folsom AR; Heiss G; Selvin E; Lutsey PL; Coresh J; Matsushita K
    Atherosclerosis; 2017 Dec; 267():167-174. PubMed ID: 28992939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers of Vitamin D Status and Risk of ESRD.
    Rebholz CM; Grams ME; Lutsey PL; Hoofnagle AN; Misialek JR; Inker LA; Levey AS; Selvin E; Hsu CY; Kimmel PL; Vasan RS; Eckfeldt JH; Coresh J;
    Am J Kidney Dis; 2016 Feb; 67(2):235-42. PubMed ID: 26475393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.
    Ärnlöv J; Carlsson AC; Sundström J; Ingelsson E; Larsson A; Lind L; Larsson TE
    Clin J Am Soc Nephrol; 2013 May; 8(5):781-6. PubMed ID: 23335040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation.
    Young A; Hodsman AB; Boudville N; Geddes C; Gill J; Goltzman D; Jassal SV; Klarenbach S; Knoll G; Muirhead N; Prasad GV; Treleaven D; Garg AX;
    Am J Kidney Dis; 2012 Jun; 59(6):761-9. PubMed ID: 22093959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.
    Nakano C; Hamano T; Fujii N; Matsui I; Tomida K; Mikami S; Inoue K; Obi Y; Okada N; Tsubakihara Y; Isaka Y; Rakugi H
    Clin J Am Soc Nephrol; 2012 May; 7(5):810-9. PubMed ID: 22362065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGF-23 levels in patients with AKI and risk of adverse outcomes.
    Leaf DE; Wolf M; Waikar SS; Chase H; Christov M; Cremers S; Stern L
    Clin J Am Soc Nephrol; 2012 Aug; 7(8):1217-23. PubMed ID: 22700885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.
    Isakova T; Xie H; Yang W; Xie D; Anderson AH; Scialla J; Wahl P; Gutiérrez OM; Steigerwalt S; He J; Schwartz S; Lo J; Ojo A; Sondheimer J; Hsu CY; Lash J; Leonard M; Kusek JW; Feldman HI; Wolf M;
    JAMA; 2011 Jun; 305(23):2432-9. PubMed ID: 21673295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Socioeconomic status and risk of kidney dysfunction: the Atherosclerosis Risk in Communities study.
    Vart P; Grams ME; Ballew SH; Woodward M; Coresh J; Matsushita K
    Nephrol Dial Transplant; 2019 Aug; 34(8):1361-1368. PubMed ID: 29897587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones.
    Taylor EN; Hoofnagle AN; Curhan GC
    Clin J Am Soc Nephrol; 2015 Apr; 10(4):667-75. PubMed ID: 25623233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Urinary Oxalate Excretion With the Risk of Chronic Kidney Disease Progression.
    Waikar SS; Srivastava A; Palsson R; Shafi T; Hsu CY; Sharma K; Lash JP; Chen J; He J; Lieske J; Xie D; Zhang X; Feldman HI; Curhan GC;
    JAMA Intern Med; 2019 Apr; 179(4):542-551. PubMed ID: 30830167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults.
    Bansal N; Katz R; Dalrymple L; de Boer I; DeFilippi C; Kestenbaum B; Park M; Sarnak M; Seliger S; Shlipak M
    Clin J Am Soc Nephrol; 2015 Feb; 10(2):205-14. PubMed ID: 25605700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function.
    Dhayat NA; Ackermann D; Pruijm M; Ponte B; Ehret G; Guessous I; Leichtle AB; Paccaud F; Mohaupt M; Fiedler GM; Devuyst O; Pechère-Bertschi A; Burnier M; Martin PY; Bochud M; Vogt B; Fuster DG
    Kidney Int; 2016 Sep; 90(3):648-57. PubMed ID: 27370409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
    Kanda E; Yoshida M; Sasaki S
    BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS).
    Mathew JS; Sachs MC; Katz R; Patton KK; Heckbert SR; Hoofnagle AN; Alonso A; Chonchol M; Deo R; Ix JH; Siscovick DS; Kestenbaum B; de Boer IH
    Circulation; 2014 Jul; 130(4):298-307. PubMed ID: 24920722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.
    Krishnasamy R; Tan SJ; Hawley CM; Johnson DW; Stanton T; Lee K; Mudge DW; Campbell S; Elder GJ; Toussaint ND; Isbel NM
    BMC Nephrol; 2017 Sep; 18(1):281. PubMed ID: 28870151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study.
    Bash LD; Erlinger TP; Coresh J; Marsh-Manzi J; Folsom AR; Astor BC
    Am J Kidney Dis; 2009 Apr; 53(4):596-605. PubMed ID: 19110358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.